Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Musculoskeletal | Neurology | Family Medicine
Search Medical Condition
Parkinson's Disease Clinical Trials
A listing of Parkinson's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (465) clinical trials
A 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Flexible Dose Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Early Stage Parkinson's Disease
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease.
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants With Early Parkinson's Disease With a 52-Week Blinded Extension
This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous RO7046015 versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of 2 parts: a 52-week, double-blind, ...
Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson’s Disease Dementia (PDD)
Multicenter, randomized, double-blind, parallel-group, placebo-controlled, fixed-dosage, Phase 2a study comparing 3 dosages of LY3154207
Open Label Parkinson's clinical research study
This study will evaluate the safety and tolerability of Tozedenant as adjunctive therapy in Levodopa treated patients.
A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease
Primary Objective: To compare the pharmacokinetics (PK) of single and multiple doses of IPX203 with Immediate release carbidopa-levodopa (IR CD-LD) in subjects with advanced Parkinson's disease (PD). Secondary Objectives: To compare the pharmacodynamics of single and multiple doses of IPX203 with IR CD-LD. To compare the efficacy of IPX203 with ...
Do you have Parkinson's disease and are you considering DBS?
Doctors at the University of Kentucky are investigating a cell therapy to modify the progression of motor and/or cognitive impairment in people with Parkinson's disease. Patients who are already planning to undergo deep brain stimulation (DBS) surgery may be eligible for this investigational procedure, which involves taking a small piece ...
Phase 4 - 16306A / NOH402: "RESTORE: A clinical study of patients with symptomatic neurogenic orthostatic hypotension to assess sustained effects Of Droxidopa therapy"
This is a study of patients with symptomatic neurogenic orthostatic hypotension.
A Washington University research study seeks participants with Parkinson’s disease.
The purpose of the study is to determine how quickly a protein called Alpha-synuclein (a-syn) is cleared from the body in participants with Parkinson’s disease. A-syn is a major component of Parkinson’s disease. There are up to 7 study visits. Participation includes neurological/physical exam, vitals, blood draws and lumbar puncture ...
A Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy and Safety of Gastric Retentive, Controlled Release Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) to Immediate Release CD/LD in Fluctuating Parkinson’s Disease Patients
The purpose of this study is to determine whether the gastric retentive Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) is more effective than the commercially available immediate release Carbidopa/Levodopa in reducing motor fluctuations such as "off time" in advanced Parkinson's Disease patients.
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Suvorexant for Insomnia in Parkinson Disease.
The purpose of this study is to see if the study drug, suvorexant, is safe and effective in treating symptoms of insomnia in people with Parkinson's Disease. It is anticipated that a total of 20 subjects, 30 to 80 years of age, with Parkinson's Disease and symptoms of insomnia will ...
